## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.05 indicates fundamental undervaluation. Quality metrics strong (ROE 82%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-3.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($330.44)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Amgen (AMGN) Stock Hits New 52â€‘Week High as Obesity Drug Bets and Analyst Upgrades Fuel 2025 Rally**
- Source: ts2.tech | 20251203T223558 | Bullish | Relevance: 100%
- Amgen (NASDAQ: AMGN) reached a new 52-week high of $345.95 on December 3, 2025, driven by strong Q3 earnings, the promising obesity drug MariTide, and analyst upgrades. While the stock's year-to-date gain is over 34%, analysts express caution due to valuation concerns and upcoming patent expirations, balancing the optimism around its pipeline and diversified growth. The future performance heavily relies on MariTide's clinical trial outcomes and the company's ability to navigate competitive and regulatory pressures.

**2. BMO Capital Adjusts Price Target on Amgen to $372 From $335, Maintains Outperform Rating**
- Source: MarketScreener | 20251203T103400 | Bullish | Relevance: 100%
- BMO Capital has increased its price target for Amgen to $372 from $335, while reiterating an Outperform rating on the stock. This adjustment reflects continued analyst confidence in the biotechnology group. The article also provides a snapshot of Amgen's stock performance and other recent news related to the company including insider transactions and FDA approvals.

**3. Biocon Biologics announces settlement agreement with Amgen Inc.**
- Source: Business Standard | 20251202T091300 | Bullish | Relevance: 100%
- Biocon Biologics, a subsidiary of Biocon, has announced a settlement agreement with Amgen Inc. This agreement paves the way for Biocon Biologics to commercialize its Denosumab biosimilars, Vevzuo and Evfraxy, in Europe and the rest of the world starting December 02, 2025. The specific terms of the settlement remain confidential.

**4. Amgen Stock (AMGN) Today: Q3 2025 Earnings Beat, MariTide Obesity Drug Outlook and 2030 Price Forecast**
- Source: ts2.tech | 20251201T221906 | Neutral | Relevance: 100%
- Amgen (AMGN) experienced a strong rally following its Q3 2025 earnings beat, with revenue reaching $9.56 billion and adjusted EPS at $5.64. Despite a recent pullback due to profit-taking, the company's growth is driven by drugs like Repatha and its biosimilar portfolio, alongside the speculative potential of its obesity drug MariTide. Analysts maintain a "Hold" rating on AMGN, with long-term forecasts suggesting significant upside by 2030, balancing strong financials against valuation concerns and competitive risks.

**5. Is the Market Bullish or Bearish on Amgen Inc?**
- Source: Sahm | 20251201T111139 | Somewhat-Bearish | Relevance: 100%
- Amgen Inc.'s short interest has increased by 16.82% since its last report, with 13.43 million shares sold short, representing 2.5% of regular shares available for trading. It would take traders 7.08 days to cover their short positions on average, indicating a growing bearish sentiment. Despite this rise in short interest, Amgen's peer group average for short interest as a percentage of float is 6.86%, suggesting the company has less short interest compared to most of its peers.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 4, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |
| 2025-11-14 | Piper Sandler | $381 | $342 | +11% |
| 2025-11-06 | Cantor Fitzgera | $315 | $305 | +3% |
| 2025-11-05 | Morgan Stanley | $329 | $333 | -1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-03 | BMO Capital | main | Outperform |
| 2025-11-14 | Piper Sandler | main | Overweight |
| 2025-11-06 | Cantor Fitzgera | main | Neutral |
| 2025-11-05 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.9% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +8%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.05 suggests fair value with growth premium. Forward P/E 15.8x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (4 raises, avg +8%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $179.3B |
| Beta | 0.45 |
| 52W Range | $257.05 - $346.38 |
| Short Interest | 2.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.05 |
| Forward P/E | 15.8 |
| Current P/E | 16.3 |
| YoY Growth | 3.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.2% to 1.4% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.6pp (needs >4.0% for momentum thesis). MRS_5 at 0.5% confirms short-term momentum alignment. AM_20 at 3.3% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.86), momentum weakening. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.35% (CS: 66) | Neutral |
| RSI_14 | 66.7 | Neutral |
| MACD Histogram | -0.86 | Bearish |
| vs SMA20 | 1.029x | Above |
| vs SMA50 | 1.116x | Above |
| vs SMA200 | 1.166x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $345.42
- **Stop Loss:** $330.44 (4.3% risk)
- **Target:** $375.38 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 63
- **Position Value:** $21,761.46
- **Portfolio %:** 21.76%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*